SCHEMBL5357397

SCHEMBL5357397

O=C1Nc2ccccc2Oc2c1cccc2N1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
GAA P10253 2/20 0.44
MAPK1 P28482 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
P2RX1 P51575 1/20 0.44
P2RX3 P56373 1/20 0.44
P2RX4 Q99571 1/20 0.44
TMEM97 Q5BJF2 3/20 0.43
SIGMAR1 Q99720 3/20 0.43
CTRB1 P17538 1/20 0.40
CYP2C19 P33261 1/20 0.40
PARP1 P09874 2/20 0.40
PARP2 Q9UGN5 1/20 0.40
HDAC1 Q13547 1/20 0.40
CXCR3 P49682 1/20 0.39
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5945010 0.84 BACE1 (0.50) MAPK1ALDH1A1MAPTBACE1
SCHEMBL5359537 0.76 ADRB1 (0.49) SIGMAR1
Hydrochloric Acid SCHEMBL5361148 0.75 ADRB1 (0.48) SIGMAR1ALDH1A1
SCHEMBL5809972 0.73 P2RX4 (0.38) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL5357553 0.72 MEN1 (0.35) GAAMEN1KMT2AMAPTL3MBTL1
SCHEMBL10524643 0.72 NPSR1 (0.46) SMN1; SMN2NPC1RAB9AGAAMAPK1
SCHEMBL30797016 0.72 TMEM97 (0.57) SMN1; SMN2NPC1RAB9AGAAMAPK1
SCHEMBL5362589 0.71 SMN1; SMN2 (0.72) SMN1; SMN2NPC1RAB9AGAAMEN1
SCHEMBL4814264 0.70 MEN1 (0.76) SMN1; SMN2NPC1RAB9AGAAMEN1
SCHEMBL3970912 0.70 MEN1 (0.76) SMN1; SMN2NPC1RAB9AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC 2006-07-13 US disclosed
WO-2006061126-A2 DIBENZOXAZEPINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof HTR6, BDKRB1, HTR7 SMN1; SMN2 4514/4885NPC1 3148/4885RAB9A 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.